PE20210125A1 - Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos - Google Patents
Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estosInfo
- Publication number
- PE20210125A1 PE20210125A1 PE2020000380A PE2020000380A PE20210125A1 PE 20210125 A1 PE20210125 A1 PE 20210125A1 PE 2020000380 A PE2020000380 A PE 2020000380A PE 2020000380 A PE2020000380 A PE 2020000380A PE 20210125 A1 PE20210125 A1 PE 20210125A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- cancer
- drug
- antibody conjugates
- activable antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572467P | 2017-10-14 | 2017-10-14 | |
| PCT/US2018/055733 WO2019075417A1 (en) | 2017-10-14 | 2018-10-12 | CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210125A1 true PE20210125A1 (es) | 2021-01-19 |
Family
ID=64110112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000380A PE20210125A1 (es) | 2017-10-14 | 2018-10-12 | Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos |
Country Status (36)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| CN110809583A (zh) | 2017-06-07 | 2020-02-18 | 瑞泽恩制药公司 | 用于内化酶的组合物和方法 |
| PH12020550417A1 (en) * | 2017-10-14 | 2021-04-12 | Abbvie Inc | Anti-cd71 activatable antibody drug conjugates and methods of use thereof |
| KR20200118151A (ko) | 2018-02-07 | 2020-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 치료 단백질 전달을 위한 방법 및 조성물 |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| MX2020012350A (es) | 2018-05-17 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-cd63, conjugados y usos de estos. |
| MX2022012635A (es) * | 2020-04-08 | 2023-01-11 | Aliada Therapeutics Inc | Composiciones y métodos para distribución de barrera hematoencefálica. |
| KR20220166814A (ko) | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| AU2022388735A1 (en) | 2021-11-09 | 2024-05-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| JP2025528052A (ja) * | 2022-07-29 | 2025-08-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 脳及び筋肉へのトランスフェリン受容体（ｔｆｒ）媒介送達のための組成物及び方法 |
| WO2025024334A1 (en) | 2023-07-21 | 2025-01-30 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025133132A1 (en) * | 2023-12-20 | 2025-06-26 | Institut National De La Sante Et De La Recherche Medicale | Novel anti-tfr1 (cd71) antibodies for cancer treatment |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| BRPI0820270A2 (pt) * | 2007-11-07 | 2015-06-16 | Celldex Therapeutics Inc | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US8765916B2 (en) * | 2009-04-29 | 2014-07-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| CA2826186C (en) * | 2011-02-01 | 2020-08-04 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
| DK2809683T3 (en) * | 2012-01-31 | 2018-12-10 | Sbi Biotech Co Ltd | ANTI-phospholipase D 4 ANTIBODY |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| CN103145847B (zh) * | 2013-02-05 | 2014-05-21 | 浙江大学 | 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用 |
| PT3088419T (pt) * | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| CN106237341B (zh) * | 2016-07-12 | 2019-07-30 | 浙江大学 | 一种抗体偶联药物及其制备方法和应用 |
| PH12020550417A1 (en) * | 2017-10-14 | 2021-04-12 | Abbvie Inc | Anti-cd71 activatable antibody drug conjugates and methods of use thereof |
-
2018
- 2018-10-12 PH PH1/2020/550417A patent/PH12020550417A1/en unknown
- 2018-10-12 PL PL18797311T patent/PL3691692T3/pl unknown
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/ko not_active Withdrawn
- 2018-10-12 ES ES18797311T patent/ES2864013T3/es active Active
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/ko active Active
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/pt active IP Right Grant
- 2018-10-12 CR CR20200206A patent/CR20200206A/es unknown
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/ko not_active Ceased
- 2018-10-12 AR ARP180102966A patent/AR115178A1/es not_active Application Discontinuation
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/ru active
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/hu unknown
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en not_active Ceased
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/es unknown
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 RS RS20210341A patent/RS61596B1/sr unknown
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/ko active Active
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en not_active Withdrawn
- 2018-10-12 CN CN201880069577.4A patent/CN111278467B/zh active Active
- 2018-10-12 MA MA50752A patent/MA50752B1/fr unknown
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/lt unknown
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/es unknown
- 2018-10-12 TW TW111137633A patent/TW202330039A/zh unknown
- 2018-10-12 SI SI201830233T patent/SI3691692T1/sl unknown
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en not_active Abandoned
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/hr unknown
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/ro unknown
- 2018-10-12 UY UY0001037931A patent/UY37931A/es not_active Application Discontinuation
- 2018-10-12 PT PT187973110T patent/PT3691692T/pt unknown
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 SM SM20210184T patent/SMT202100184T1/it unknown
- 2018-10-12 TW TW107136020A patent/TWI780237B/zh not_active IP Right Cessation
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/da active
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/ja active Active
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/ru unknown
-
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/es unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/es unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/es unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
-
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/el unknown
-
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en not_active Abandoned
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/es unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210125A1 (es) | Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos | |
| MX2013002535A (es) | Nuevas proteinas de union a antigenos. | |
| CY1124402T1 (el) | Προϊοντα συζευξης πυρρολοβενζοδιαζεπινης-αντισωματος | |
| CY1120123T1 (el) | Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| CY1121663T1 (el) | Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate | |
| EA201690080A1 (ru) | Применение молекул, ингибирующих семафорин-4d, в комбинации с иммуномодулирующей терапией для ингибирования роста и метастазирования опухолей | |
| CO7160045A2 (es) | Anticuerpos activable que se unen al receptor del factor de crecimiento epidérmico y métodos de uso de los mismos | |
| BR112019005697A2 (pt) | anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16 | |
| AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
| AR080513A1 (es) | Moleculas de union cd37 y sus inmunoconjugados | |
| MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
| PE20181953A1 (es) | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| NZ729243A (en) | Novel glycan conjugates and use thereof | |
| MX2011010469A (es) | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| WO2016059602A3 (en) | Combination therapy with anti-her3 antibodies to treat cancer | |
| CL2021001260A1 (es) | Anticuerpos anti-sirpa humanizados | |
| EA201691384A2 (ru) | Конструкции варианта sirp-альфа и их применение | |
| CU20160042A7 (es) | Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer | |
| EA201390694A1 (ru) | Способы лечения рака | |
| CO2020000517A2 (es) | Fragmento fab de anticuerpo anti-ceacam5 de humano novedoso | |
| CR20200623A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
| AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer |